Cargando…

PB2283: COVID-19 (SARS-COV-2 INFECTION) IN LYMPHOMA PATIENTS

Detalles Bibliográficos
Autores principales:	Tytorenko, I., Kryachоk, I., Alexik, O., Kadnikova, T., Martynchik, A., Novosad, O., Pastyshenko, Y., Stepanishina, Y., Shokun, N., Filonenko, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431443/ http://dx.doi.org/10.1097/01.HS9.0000851960.44029.ad

Ejemplares similares

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022)

PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.
por: Novosad, Olga, et al.
Publicado: (2023)

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP
por: Filonenko, K., et al.
Publicado: (2022)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2283: IN THE ERA OF IMMUNOPHENOTYPING AND MOLECULAR DIAGNOSTICS DOES MORPHOLOGY PLAY AN ESSENTIAL ROLE IN DIFFERENTIATING HAIRY CELL LEUKEMIA FROM ITS MIMICS?
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2135: BURKITT LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (BL-IPI): IS IT EFFICIENT ENOUGH IN ADULT BURKITT LYMPHOMA PATIENTS?
por: Sayinalp, B., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB2124: MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA
por: Liang, J., et al.
Publicado: (2022)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

PB2270: CLEARANCE OF PERSISTENT SARS-COV2 INFECTION WITH ANTIBODY CONTAINING PLASMA IN LEUKEMIA AND LYMPHOMA PATIENTS
por: Janssen, M., et al.
Publicado: (2022)

PB2257: SARS-COV-2 VARIANTS DETECTED IN EMPLOYEES OF ONE MEDICAL CENTER
por: Biderman, B., et al.
Publicado: (2022)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB2107: CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA
por: Liu, J., et al.
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB1791: ON THE ISSUE OF HOUSEKEEPING GENE PRIMER DESIGN FOR ADEQUATE ASSESSMENT OF THE EXPRESSION OF THE CHIMERIC TRANSCRIPTS.
por: Fevraleva, I., et al.
Publicado: (2022)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2094: PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Charfi, M., et al.
Publicado: (2022)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

PB1819: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN SOUTHERN TUNISIA
por: kasser, O., et al.
Publicado: (2022)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

PB1853: IN-HOSPITAL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND CONCOMITANT CORONAVIRUS INFECTION DEPENDING ON VARIOUS CLINICAL FACTORS.
por: Baryakh, E., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2029: MULTIPLE MYELOMA AND SPINAL CORD COMPRESSION: THE EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Kallel, F., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Yevstakhevych, Yuriy, et al.
Publicado: (2023)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
por: Zamanillo, I., et al.
Publicado: (2022)

PB2077: POD12 AND POD24 – A NEW SURROGATE MARKER IN MANTLE CELL LYMPHOMA TREATMENT?
por: Freitas, J., et al.
Publicado: (2022)

PB2078: A RETROSPECTIVE ANALYSIS OF THE EFFICACY OF LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE FOR TREATMENT IN PATIENTS WITH LOW GRADE NON-HODGKIN LYMPHOMA
por: Han, B., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB2142: CLINICAL CHARACTERISTICS AND OUTCOMES OF NEWLY DIAGNOSED PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED LYMPHOMA ADMINISTERED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
por: Wang, C., et al.
Publicado: (2022)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2268: IMPACT OF HEMATOLOGICAL DISORDERS ON MORTALITY AND SERIOUS OUTCOMES IN SARS-COV-2 INFECTION: A MULTICENTER COHORT STUDY
por: Hernandez Perez, A. P., et al.
Publicado: (2022)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hmk89a3kc918n8qsfc057u0k3v